SCHEDULE: Whetstone Capital Pushes Health Catalyst Governance Overhaul

Sentiment:

Activist Investor Filing 21 January 2026 8:39 AM

Activist investor Whetstone Capital Advisors, holding a 7.4% stake in Health Catalyst, proposes significant corporate governance reforms including board declassification and CEO/Chair separation.

Summary

Whetstone Capital Advisors, LLC and David Atterbury (Reporting Persons) beneficially own 5,265,377 shares of Health Catalyst, Inc. common stock, representing 7.4% of the outstanding shares.
The investment, totaling approximately $15,701,426, was initially made for investment purposes.
The Reporting Persons intend to submit a proposal to improve corporate governance at Health Catalyst, Inc. for a vote at the next annual or special meeting of shareholders.
The proposal includes immediate declassification of the Board of Directors, a majority vote requirement for amending the Certificate of Incorporation and Bylaws, shareholder ability to call special meetings and approve actions by written consent, separation of the CEO and Board Chair roles, and term limits for directors and Nominating and Corporate Governance Committee members.
The Reporting Persons notified the company on January 15, 2026, and requested the proposal be included in the proxy statement under SEC Rule 14a-8.
They hold 15,150 long options exercisable for 1,515,000 shares until December 18, 2026, and have sold short 30,300 for Common Stock exercisable until December 18, 2026.

Sentiment

Score: 7

Explanation: The filing indicates an activist investor is pushing for significant corporate governance improvements, which is generally viewed positively by the market as it can lead to enhanced shareholder value and accountability. While it introduces potential for conflict, the proposed changes are largely aligned with best governance practices.

Positives

Activist investor engagement often leads to increased scrutiny and potential improvements in corporate governance, which can enhance long-term shareholder value.
Proposals such as board declassification, majority vote for charter amendments, and shareholder rights to call special meetings or act by written consent generally align with best practices for corporate governance and shareholder empowerment.
Separation of CEO and Board Chair roles can improve independent oversight and accountability.
Term limits for directors can promote fresh perspectives and prevent entrenchment.

Negatives

The filing itself does not present negative financial or operational results for Health Catalyst, Inc.
Activist campaigns can sometimes create short-term distractions for management, potentially diverting focus from core business operations.

Risks

Potential for a proxy contest or prolonged disagreement between the Reporting Persons and Health Catalyst's management/Board, which could create uncertainty.
The company may incur costs associated with responding to the proposal and engaging with the activist investor.
Uncertainty regarding the outcome of the proposed governance changes and their actual impact on company performance.

Future Outlook

The Reporting Persons intend to continue reviewing their investment in Health Catalyst, Inc. and may take further actions, including purchasing or selling shares, engaging in hedging transactions, or proposing additional actions to management and the Board, depending on various factors such as the Issuer's financial position, strategic direction, and market conditions. Their immediate future outlook involves pursuing the proposed corporate governance changes.

Industry Context

Activist investor campaigns, particularly those focused on corporate governance, are a recurring theme across various industries, including healthcare technology. Such filings often signal that a significant shareholder believes the company's current governance structure is suboptimal and could be improved to unlock greater shareholder value. This type of engagement can put pressure on management and the board to consider changes that might align more closely with shareholder interests.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Proposed Bylaw Amendments	Immediate declassification of the Board of Directors.	Next annual or special meeting of shareholders (if approved)	Would transition the board from staggered terms to annual elections, increasing accountability to shareholders.
Proposed Bylaw Amendments	Majority vote to amend the Certificate of Incorporation and Bylaws.	Next annual or special meeting of shareholders (if approved)	Would empower shareholders by requiring a simple majority for significant corporate charter changes, rather than potentially higher thresholds.
Proposed Bylaw Amendments	Ability of shareholders to call special meetings of shareholders.	Next annual or special meeting of shareholders (if approved)	Would provide shareholders with a mechanism to address urgent matters outside of the annual meeting cycle.
Proposed Bylaw Amendments	Ability of shareholders to approve actions by written consent.	Next annual or special meeting of shareholders (if approved)	Would allow shareholders to take action without a formal meeting, increasing efficiency and responsiveness.
Proposed Bylaw Amendments	Separation of the office of Chief Executive Officer and Chair of the Board of Directors.	Next annual or special meeting of shareholders (if approved)	Would enhance independent oversight of management by separating the leadership roles, potentially improving corporate governance and reducing conflicts of interest.
Proposed Bylaw Amendments	Term limits for directors and members of the Nominating and Corporate Governance Committee.	Next annual or special meeting of shareholders (if approved)	Would promote board refreshment and prevent entrenchment, bringing in new perspectives and expertise.

Stakeholder Impact

Shareholders: Potential for increased shareholder value through improved corporate governance, greater accountability, and enhanced shareholder rights. Could also lead to short-term volatility due to activist engagement.
Management/Board: Will face increased scrutiny and pressure to respond to the proposed governance changes. May need to dedicate resources to address the activist campaign.
Employees, Customers, Suppliers, Creditors: Unlikely to have direct immediate impact, but long-term governance improvements could lead to a more stable and well-managed company, indirectly benefiting these stakeholders.

Next Steps

The Reporting Persons intend to submit a proposal to improve corporate governance at Health Catalyst, Inc. for a vote at the next annual or special meeting of shareholders.
They request the Company include the proposal in the proxy statement for the next annual or special meeting of shareholders pursuant to SEC Rule 14a-8.
A representative of the Reporting Persons intends to appear in person at that meeting to present the proposal.
The Reporting Persons may have further communications with officers and directors of the Issuer, other stockholders, or third parties.
They may reconsider and change their intentions, or take further actions regarding their investment position, including buying or selling shares.

Key Dates

Date	Description
11/05/2025	Date as of which 70,730,884 shares of Common Stock were issued and outstanding, as reported in the Issuer's Form 10-Q.
11/10/2025	Date Health Catalyst, Inc. filed its Quarterly Report on Form 10-Q with the SEC.
01/15/2026	Date Whetstone Capital Advisors and David Atterbury notified Health Catalyst, Inc. of their intent to submit a corporate governance proposal and sent a cover letter to the Board.
01/17/2026	Date of the proposed Bylaw Resolution by Whetstone Capital Advisors, LLC and Mr. David Atterbury.
01/20/2026	Date the Schedule 13D was signed by Whetstone Capital Advisors, LLC and David Atterbury.
12/18/2026	Expiration date for long options exercisable for 1,515,000 shares of Common Stock and short options for 30,300 shares.

Recommendation

hold

The filing indicates an activist investor is pushing for significant corporate governance reforms at Health Catalyst. While these proposed changes, such as board declassification and separation of CEO/Chair roles, are generally positive for long-term shareholder value and align with best governance practices, the outcome of this activist campaign is uncertain. The process could lead to short-term volatility or distractions for management. Investors should hold to observe how the company responds to these proposals and the potential for a proxy contest, as the immediate impact and successful implementation of these changes are not guaranteed.

Keywords

Health Catalyst, Whetstone Capital Advisors, Activist Investor, Corporate Governance, Schedule 13D, Board Declassification, Shareholder Rights, Proxy Contest, Investment, Healthcare Technology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.